McDermott advises Sensorion in connection with its EUR 18.1million capital increase

Overview


McDermott Will & Emery assisted Sensorion, a biotech company specializing in innovative therapies to restore, treat and prevent inner ear disorders, in its €18.1 million capital increase subscribed by its main investors Invus, Sofinnova Crossover I SLP, as well as by new investors including Chinese investors WuXi AppTec and 3SBio.

This capital increase expanded Sensorion’s liquidity horizon, following its €20 million fundraising in June 2019 in the form of convertible bonds, which were subscribed by Invus Public Equities LP and Sofinnova Crossover I SLP funds.

The McDermott Will & Emery team assisting Sensorion in these two fundraising events was composed of Emmanuelle Trombe and Bertrand Delafaye, Partners, as well as Fanny Rech and Mathilde Peschard.

Invus was assisted by Jones Day, with Jean-Gabriel Griboul and Anne Kerneur.

About McDermott


McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. With more than20 locations on three continents, our team works seamlessly across practices, industries and geographies to deliver highly effective—and often unexpected—solutions that propel success. More than 1,100 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.